AbCellera Biologics (ABCL) Net Income towards Common Stockholders (2020 - 2026)

AbCellera Biologics (ABCL) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$43.2 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 5.38% year-over-year to -$43.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$144.0 million (up 14.24% YoY) and the FY2025 annual result came in at -$146.4 million, up 10.1% from the prior year.
• Net Income towards Common Stockholders retreated to -$43.2 million in Q1 2026, from -$8.9 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $168.6 million in Q1 2022 to a low of -$57.1 million in Q3 2025.
• A 5-year average of -$20.0 million and a median of -$34.7 million in 2025 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders jumped 224.53% — and 2023, when it tumbled 349.93%.
• Tracing ABCL's Net Income towards Common Stockholders over 5 years: stood at -$29.9 million in 2022, then sank by 57.73% to -$47.2 million in 2023, then rose by 27.44% to -$34.2 million in 2024, then surged by 73.85% to -$8.9 million in 2025, then tumbled by 382.56% to -$43.2 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$43.2 million (Q1 2026), -$8.9 million (Q4 2025), and -$57.1 million (Q3 2025), per Business Quant data.